JP2022529726A5 - - Google Patents
Info
- Publication number
- JP2022529726A5 JP2022529726A5 JP2021562911A JP2021562911A JP2022529726A5 JP 2022529726 A5 JP2022529726 A5 JP 2022529726A5 JP 2021562911 A JP2021562911 A JP 2021562911A JP 2021562911 A JP2021562911 A JP 2021562911A JP 2022529726 A5 JP2022529726 A5 JP 2022529726A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- amino acid
- binding fragment
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838264P | 2019-04-24 | 2019-04-24 | |
| US62/838,264 | 2019-04-24 | ||
| US201962841733P | 2019-05-01 | 2019-05-01 | |
| US62/841,733 | 2019-05-01 | ||
| PCT/US2020/029648 WO2020219770A1 (en) | 2019-04-24 | 2020-04-23 | Anti-cd117 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529726A JP2022529726A (ja) | 2022-06-23 |
| JP2022529726A5 true JP2022529726A5 (https=) | 2022-09-20 |
| JPWO2020219770A5 JPWO2020219770A5 (https=) | 2022-09-20 |
Family
ID=72941829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562911A Withdrawn JP2022529726A (ja) | 2019-04-24 | 2020-04-23 | Ａｎｔｉ－ｃｄ１１７とその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220177575A1 (https=) |
| EP (1) | EP3958902A4 (https=) |
| JP (1) | JP2022529726A (https=) |
| CN (1) | CN114007644A (https=) |
| AU (1) | AU2020261405A1 (https=) |
| CA (1) | CA3134319A1 (https=) |
| WO (1) | WO2020219770A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121555430A (zh) | 2018-05-11 | 2026-02-24 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| US10421802B2 (en) * | 2013-10-18 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides |
| CA3079897A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
-
2020
- 2020-04-23 CA CA3134319A patent/CA3134319A1/en active Pending
- 2020-04-23 AU AU2020261405A patent/AU2020261405A1/en not_active Abandoned
- 2020-04-23 CN CN202080044160.XA patent/CN114007644A/zh active Pending
- 2020-04-23 EP EP20796149.1A patent/EP3958902A4/en not_active Withdrawn
- 2020-04-23 WO PCT/US2020/029648 patent/WO2020219770A1/en not_active Ceased
- 2020-04-23 JP JP2021562911A patent/JP2022529726A/ja not_active Withdrawn
-
2021
- 2021-10-22 US US17/452,045 patent/US20220177575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641452B2 (ja) | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 | |
| US11572411B2 (en) | Anti-CD117 antibodies and conjugates | |
| JP7791923B2 (ja) | Ｃｄ５＋細胞の枯渇のための組成物および方法 | |
| JP7669269B2 (ja) | 抗－ｃｄ４５抗体及びそのコンジュゲート | |
| JP2025160215A (ja) | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 | |
| TWI904109B (zh) | 抗ｃｄ４５抗體及其結合物 | |
| JP2021500375A5 (https=) | ||
| JP2022529726A5 (https=) | ||
| US20220177575A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022530443A5 (https=) | ||
| US20220177578A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022529727A5 (https=) | ||
| JPWO2020219770A5 (https=) | ||
| JPWO2021087368A5 (https=) | ||
| JPWO2020219778A5 (https=) | ||
| JPWO2020219748A5 (https=) | ||
| JPWO2020219774A5 (https=) |